An interventional study of Esmolol and Placebo in Sepsis, sponsored by Shanghai Zhongshan Hospital. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-03.
Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Treatment
The investigators conduct an RCT to explore the efficacy of esmolol in patients with septic shock and sepsis.
Severe sepsis, septic shock, and their complications have become the major healthcare problem that affects millions of people each year, resulting in high mortality rates. Septic responses have an extremely complex chain of events including inflammatory and anti-inflammatory processes, humoral and cellular reactions, and cardiocirculatory abnormalities. Esmolol may have some potential in treating septic shock and sepsis. The investigators conduct an RCT to explore the efficacy of esmolol in patients with septic shock and sepsis.
1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.
This study's planned enrollment of 120 is above the median of 105 across 896 interventional studies indexed under Sepsis.
Browse Sepsis studies →Shanghai Zhongshan Hospital is the lead sponsor of 636 studies on the registry; 283 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients randomly assigned to the ES group were treated with esmolol to control the heart rate to the target range.
Drug: Esmolol
Patients randomly assigned to the control group were treated with placebo.
Drug: Placebo
The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.
Placebo
REE
Resting energy expenditure
Time frame: Day 7 after enrollment
28-day mortality rate
28-day mortality rate
Time frame: Day 28 after enrollment
HR control rate
target heart rate control rate
Time frame: 24 hours after enrollment
Vasoactive drug administration dose
Vasoactive drug administration dose
Time frame: Day 1/3/7 after enrollment
Concentration of Lac
Concentration of lactic acid
Time frame: Day 1/3/7 after enrollment
O2ER
oxygen extraction rate
Time frame: Day 1/3/7 after enrollment
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Zhongshan Hospital